Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has concluded patient recruitment in a multi-center, randomized, vehicle controlled Phase 2C trial evaluating PH-10 as a treatment for psoriasis.
Subscribe to our email newsletter
The company has recruited around 90 patients at four sites which include Mount Sinai School of Medicine in New York City, Wake Research Associates in Raleigh, NC, Dermatology Specialists in Oceanside, CA and International Dermatology Research in Miami, FL.
In the trial, subjects have been randomized sequentially by center to one of four treatment cohorts, in order to assess efficacy and safety of topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.
Provectus CEO Craig Dees said they expect the results of this clinical trial will help define the commercial viability of PH-10 for psoriasis, and will be an integral part of discussions that they are having with potential out-licensing partners.